Evgen Pharma PLC Publication of data in glioblastoma cells
20 Septiembre 2021 - 1:00AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
20 September 2021
Evgen Pharma plc
("Evgen" or the "Company")
Publication shows effectiveness of SFX-01 in patient derived
glioblastoma cells
University of Auckland data
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company developing sulforaphane based medicines for the treatment
of multiple diseases, notes the publication of data in glioblastoma
cells (GBM) generated by Dr Euphemia Leung and Prof Bruce Baguley
of the University of Auckland, New Zealand in the pre-print journal
BioRxIV (Leung, Wright and Baguley, 2021
https://www.biorxiv.org/content/10.1101/2021.09.14.459936v1).
The in vitro data show effectiveness of the Company's lead asset
SFX-01 in glioblastoma cells and 3D spheroids from several patients
in New Zealand, together with the more commonly used commercially
available cell lines. 3D spheroids are aggregations of tumour cells
that more closely reflect the structure of tumours in patients. In
these in vitro experiments, SFX-01 demonstrated inhibition of
glioblastoma cell growth, confirming work previously announced by
the Company in another academic centre.
Evgen recently announced the grant of Orphan Drug Designation in
the USA for Malignant Glioma, affording the programme additional
data protection and other incentives.
Dr Huw Jones, CEO of Evgen, commented: "This careful and
well-controlled set of experiments by Dr Leung and Prof Baguley
confirm work communicated to us by Dr Festuccia of the University
of L'Aquila, Abruzzo, Italy and are now available through the rapid
publication BioRxIV. We noted the effects observed by the Auckland
group in a previous communication and the data are now available
for inspection via the journal. They serve to confirm the potential
efficacy of SFX-01 in cells that are arguably more disease relevant
than those more commonly used."
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Dr Huw Jones, CEO
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7876 741 001 / +44 (0)7980
Anna Dunphy / Paul McManus 541 893
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The has its headquarters at Alderley Park, Cheshire, and its
registered office is at the Liverpool Science Park, Liverpool. It
is listed on the AIM market of the London Stock Exchange and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAZZGMLDNGGMZM
(END) Dow Jones Newswires
September 20, 2021 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024